Evotec-Secarna: new partnership in antisense oligonucleotide-based therapeutics The German companies Evotec and  Secarna Pharmaceuticals have concluded a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Secarna, a global leader in discovering and developing next-generation ASO,  combines its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate…..